Loading clinical trials...

Quality of End-of-Life Care for Children With Cancer | Clinical Trials | Clareo Health

NOT_YET_RECRUITING

Quality of End-of-Life Care for Children With Cancer

Quality of End-of-Life Care for Children With Cancer: A COG Groupwide Observational Study

NCT07412002•Children's Oncology Group

Summary

This study examines the role of access to care, patient/family interactions with the healthcare system, and stress in explaining variations in quality of end of life care. The data collected from this study may help researchers develop a model for identifying patients at risk of low quality end of life care as well as recommendations for potential future interventions.

Detailed Description

PRIMARY OBJECTIVE: I. Examine the role of access to care, patient/family healthcare interactions, and stress in variation in quality of end-of-life (EOL) care. OUTLINE: This is an observational study. PART 1: The medical records of deceased patients are reviewed on study. PART 2: Bereaved parents complete a survey and may participate in an interview on study.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Index Child (COG Registered Patient):
•* Must be deceased
•* \< 18 years old at time of death
•* Diagnosed with any oncologic condition
•* History of enrollment on Stratum 1 of APEC14B1, Project:EveryChild
•* Note: history of treatment on a COG therapeutic trial is not required
•* Resided in the United States, including Puerto Rico, as evidenced by most recent address, at the time of death
•Bereaved Parent(s):
•Must be a parent, legal guardian, or caregiver (biological or non-biological) of an eligible Index Child enrolled on APEC14B1 with current Consent to Future Contact
•Self-reported confirmation of familiarity with the care received by the Index Child in the last month of their life
+6 more criteria

Key Dates

Start Date

July 21, 2026

Primary Completion Date

January 31, 2031

Completion Date

January 31, 2031

Last Updated

March 13, 2026

Enrollment

1,190

ESTIMATED participants

Conditions

Childhood Hematopoietic and Lymphatic System NeoplasmChildhood Malignant Solid Neoplasm

Interventions

Non-Interventional Study

OTHER

Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

NCT06620302

Childhood Fibrolamellar CarcinomaRecurrent Childhood Fibrolamellar Carcinoma+7 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 13, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions